Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jefferies Raises Questcor Pharmaceuticals (QCOR) Price Target From $50 to $52
http://www.streetinsider.com/Analyst+Comments/Jefferies+Raises+Questcor+Pharmaceuticals+(QCOR)+Price+Target+From+$50+to+$52/7370792.html
And we haven't seen these levels in four months and there is a bit of overhead here. Hopefully we can break through the 44 level and then some clear skies after that.
GLTA
GW323
Seems that way. I would like to see that short position drop here. With the entire sales force not yet out on the streets QCOR still has some big room to run for the next several quarters. We shall see.
GLTA
GW323
People were just late to the party.
OR the 30% short position is trying to keep a lid on this for a bit longer... Can't keep a lid on it forever..
So QCOR crushes it on the Quarterly and they are confident that Sales will be increasing at this pace for the next several quarters as their sales teams are still not at full staff in the field AND on a day when many are up QCOR is taking a beating on higher than average volume... What Gives....
Oh, I just figured it out, Price target got raised to $52 / share. Makes sense now. LOL. WHATEVER.
QCOR Questcor Profit Surges On Continued Sales Growth
PROVIDED BY Dow Jones & Company, Inc. - 5:19 PM 04/24/2012
DOW JONES NEWSWIRES
http://stockcharts.com/h-sc/ui?s=QCOR
Questcor Pharmaceuticals Inc.'s (QCOR) first-quarter profit more than tripled as the specialty drug maker continued to ship more of its sole drug, Acthar.
Shares still fell 3% to $40.37 after hours as investors appeared to react negatively to the company's latest volume data.
Questcor's earnings have surged in recent quarters as the drug maker expands its base of patients taking Acthar--the company's only product--which is used to treat the effects of multiple sclerosis and nephrotic syndrome, among other disorders. The company's stock price often swings depending on the amount of Acthar it ships.
The company shipped 4,111 vials of Acthar in the latest quarter, up from 2,010 vials a year earlier. Questcor said its channel inventory at the end of the latest quarter appeared higher than it did at the end of the fourth quarter.
Questcor reported a profit of $38.6 million, or 58 cents a share, up from $ 11.5 million, or 17 cents a share, a year earlier. Excluding stock-based compensation and other adjustments, earnings rose to 61 cents from 20 cents as net sales more than doubled to $96 million.
Analysts polled by Thomson Reuters expected a 52-cent per-share profit with $ 90 million of revenue.
-By Drew FitzGerald, Dow Jones Newswires
Questcor repurchased 798,285 shares of its common stock during the first quarter 2012, at an average price of $36.31 per share.
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the first quarter ended March 31, 2012. Net sales for the first quarter were $96.0 million, reflecting expanded physician usage of H.P. Acthar® Gel (Acthar) for treating serious, difficult-to- treat medical conditions. Net sales in the first quarter 2011 were $36.8 million.
GAAP net income for the first quarter of 2012 was $38.5 million or $0.58 per diluted common share. GAAP net income for the first quarter of 2011 was $11.2 million, or $0.17 per diluted common share. Non-GAAP net income for the quarter ended March 31, 2012 was $40.6 million or $0.61 per diluted common share excluding non-cash share-based compensation, depreciation and amortization expense and tax adjustments. Non-GAAP net income for the year ago quarter was $12.8 million, or $0.20 per diluted common share. Questcor repurchased 798,285 shares of its common stock during the first quarter 2012, at an average price of $36.31 per share.
<<< $QCOR Links! >>> ~ MAC's Quick DD Links without the charts.
PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/QCOR
OTC Markets Company Info ~ http://www.otcmarkets.com/stock/QCOR/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/QCOR/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/QCOR/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/QCOR/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/QCOR/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/QCOR/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/QCOR/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/QCOR/research
Google Finance Summary ~ http://www.google.com/finance?q=QCOR
Google Finance News ~ http://www.google.com/finance/company_news?q=QCOR
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=QCOR
Google Finance Financials ~ http://www.google.com/finance?q=QCOR&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=QCOR
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=QCOR&histperiod=weekly#
Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=QCOR+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=QCOR+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=QCOR+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=QCOR
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=QCOR+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=QCOR+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/QCOR
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/QCOR
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=QCOR+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=QCOR+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=QCOR+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=QCOR+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=QCOR+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=QCOR+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=QCOR+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=QCOR+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=QCOR+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=QCOR+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=QCOR+Cash+Flow&annual
FINVIZ ~ http://finviz.com/quote.ashx?t=QCOR&ty=c&ta=0&p=d
Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=QCOR
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=QCOR
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=QCOR
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=QCOR
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=QCOR
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=QCOR&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260
CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=QCOR&exchange=US
Barchart Quote ~ http://barchart.com/quotes/stocks/QCOR?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/QCOR
Barchart Options Quotes ~ http://barchart.com/options/stocks/QCOR
Barchart Technical Chart ~ http://barchart.com/charts/stocks/QCOR&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/QCOR&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/QCOR
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=QCOR
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/QCOR
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/QCOR
Barchart News Headlines ~ http://barchart.com/news/stocks/QCOR
Barchart Profile ~ http://barchart.com/profile//QCOR
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=QCOR&view=key_statistics
OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=QCOR&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=QCOR&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=QCOR&MarketTicker=NYSE&Typ=S
Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/QCOR/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/QCOR/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/QCOR/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/QCOR/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/QCOR
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/QCOR/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/QCOR/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/QCOR/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/QCOR/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/QCOR/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/QCOR/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=QCOR&sid=1795093&framed=False
The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=QCOR
Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=QCOR
StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=QCOR&num1=567&cobrand=&mode=stock
StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=QCOR
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=QCOR
AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=QCOR&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8
Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=QCOR.PK&WTmodLOC=C4-Officers-5
StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=QCOR®ion=U
Search NASDAQ ~ http://www.nasdaq.com/symbol/QCOR
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/QCOR/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/QCOR/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/QCOR/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=QCOR&selected=QCOR
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=QCOR&selected=QCOR
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/QCOR/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/QCOR/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/QCOR/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/QCOR/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/QCOR/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/QCOR/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/QCOR/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/QCOR/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/QCOR/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/QCOR/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/QCOR/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/QCOR/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/QCOR/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/QCOR/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=QCOR&selected=QCOR
NASDAQ Financials ~ http://www.nasdaq.com/symbol/QCOR/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/QCOR/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/QCOR/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/QCOR/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/QCOR/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/QCOR/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/QCOR/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/QCOR/insider-trades/sells
The Motley Fool ~ http://caps.fool.com/Ticker/QCOR.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/QCOR/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/QCOR/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/QCOR/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/QCOR/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/QCOR/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/QCOR/Statements.aspx?source=icasittab0000009
MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=QCOR
YCharts ~ http://ycharts.com/companies/QCOR
YCharts Performance ~ http://ycharts.com/companies/QCOR/performance
YCharts Dashboard ~ http://ycharts.com/companies/QCOR/dashboard
InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=QCOR&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=QCOR&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=QCOR&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=QCOR
Zacks Quote ~ http://www.zacks.com/stock/quote/QCOR
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=QCOR
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=QCOR
Knobias ~ http://knobias.10kwizard.com/files.php?sym=QCOR
StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=QCOR
Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/QCOR/HOT_TOPIC.html
Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=QCOR&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=QCOR®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=QCOR®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=QCOR®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=QCOR®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=QCOR®ion=USA&culture=en-us
CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=QCOR
TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=QCOR
OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=QCOR&searcharea=e&image1.x=0&image1.y=0
Insidercow ~ http://www.insidercow.com/history/company.jsp?company=QCOR&B1=Search%21
Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=QCOR
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=QCOR&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null
YouTube Symbol Search ~ http://www.youtube.com/results?search_query=QCOR
Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=QCOR
Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=QCOR
Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=QCOR
Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=QCOR
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=QCOR
Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=QCOR
Investorpoint ~ http://www.investorpoint.com/ enter "QCOR" and click search.
Hotstocked ~ http://www.hotstocked.com/ enter "QCOR" and click search.
Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=QCOR
Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=QCOR
DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=QCOR
SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=QCOR
OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=QCOR
Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "QCOR" and click search.
http://www.coordinatedlegal.com/SecretaryOfState.html
http://regsho.finra.org/regsho-Index.html
http://www.shortsqueeze.com/?symbol=QCOR&submit=Short+Quote%99
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=QCOR
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=QCOR
Check those searches for recent QCOR mentions. If QCOR is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
MACDlinks
~ Tuesday! $QCOR ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!
~ $QCOR ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=QCOR&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=QCOR&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=QCOR
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=QCOR#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=QCOR+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=QCOR
Finviz: http://finviz.com/quote.ashx?t=QCOR
~ BusyStock: http://busystock.com/i.php?s=QCOR&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=QCOR >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
Hi ronpopeil
How do you think the numbers will be on Tuesday evening
Share Buy Back and more product ship is a win win imo. The numbers released at the end of the month should look nice.
hope you made out well dude. sold off all my calls.
THANKS AGAIN MR. BAILEY!
They filed a 13G under Rule 13d-1b.
Rule 13d-1b(2)says:
"The Schedule 13G filed pursuant to paragraph (b)(1) of this section shall be filed within 45 days after the end of the calendar year in which the person became obligated under paragraph (b)(1) of this section to report the person's beneficial ownership as of the last day of the calendar year, Provided, That it shall not be necessary to file a Schedule 13G unless the percentage of the class of equity security specified in paragraph (i) of this section beneficially owned as of the end of the calendar year is more than five percent; However, if the person's direct or indirect beneficial ownership exceeds 10 percent of the class of equity securities prior to the end of the calendar year, the initial Schedule 13G shall be filed within 10 days after the end of the first month in which the person's direct or indirect beneficial ownership exceeds 10 percent of the class of equity securities, computed as of the last day of the month."
http://taft.law.uc.edu/CCL/34ActRls/rule13d-1.html
Ron Can you confirm: I checked the sec filings those were filed on feb 10: are these 5% ownership for Blackrock and Vanguard was as of Dec 31.
How to confirm that info.
What i thought was institutions must file with SEC within 7days of the transaction is that true?
QCOR one drug wonder : CNBC - Don Bailey
http://video.cnbc.com/gallery/?video=3000057860
BlackRock Bought:4,775,604 shares represents : 7.61% of total holdings.
Vangaurd bought addtional: 76,335 shares, now there total holdings are 3,337,563 shares
http://www.nasdaq.com/symbol/qcor/sec-filings
Two possiblities next two weeks:
1. relatively small sell off (bad news already factored in)
2. Extreme short squeeze driving stock up.
From flyonthewall
Questcor sees Q4 operating income 'approximately' $41M-$43M vs. $29.3M year-ago
Sees Q4 revenue $75M vs. consensus $68.16M :theflyonthewall.
QCOR
Questcor Pharmaceuticals, Inc. QCOR: $34.60
Buy Price Target: $57.00
QCOR: Comments from Meetings with Management
THINK ACTION:
We recently spent some time with the CEO of Questcor, Don Bailey, meeting with clients and we come away from our meetings incrementally more positive on the prospects for Acthar specifically, and for QCOR overall. We believe that concerns around the marketing of Acthar are largely unfounded based on our meeting with some regional sales representatives from both the Nephrotic Syndrome (NS) group and the Multiple Sclerosis (MS) group and that the sales reps are marketing Acthar within the label and industry norms. We are reiterating our Buy rating on shares of QCOR and our $57 PT.
KEY POINTS:
Acthar reps are experienced, and well aware of how to appropriately market Acthar, in our view. We had the opportunity to meet with both an NS rep and an MS rep to discuss their thoughts on the marketing & compliance at QCOR and we come away impressed with the experience and maturity level of the reps we met and their understanding of how to appropriately and best market Acthar to their detail doctors. The average rep at QCOR has approximately 10 years experience in the industry, has worked at some of the top names in the biotech space prior to joining QCOR, and each appeared to us to employ a “low key” approach to presenting the available data to their detail docs. The reps employed the (admittedly limited) Acthar data and case studies to help doctors to be able to identify appropriate patient candidates among their patient population, and then suggested trying Acthar for these candidates. This appeared to us to be a far cry from an “aggressive” strategy of “ambushing” doctors with Acthar.
Selling the product and the data that they have. In the words of the inimitable Donald Rumsfeld “you go to war with the army you have, not the army you might want or wish to have” and we believe that this applies to Acthar as well. While it remains true that the supporting data around Acthar is not as strong as the data supporting some other drugs, that does not take away the fact that Acthar is FDA approved for ~19 separate indications (down from 50+ prior to 2010). QCOR is allowed to market for those 19 indications and CEO Bailey re-affirmed that all reps are fully compliant with marketing regulations and that all Acthar promotional materials are submitted to the FDA’s Office of Prescription Drug Promotion (OPDP), formerly the Division of Drug Marketing and Communication (DDMAC).
We expect the web blog has run its course. While it’s not for us to speculate on the motivations of a web blog, we found little in either article to dissuade us from our conviction that QCOR continues to represent one of the more interesting opportunities in our specialty pharma coverage group. We continue to see significant growth prospects in both NS and MS and note that the early 2012 NS sales force expansion could lead to meaningful upside to our $106M 2012E NS sales projections and $2.20 EPS projections.
Reiterate Buy rating and $57 price target. We continue to see QCOR as a top pick in our specialty pharma group with an estimated 40% EPS CAGR over 2011E-2014E based on what we believe are modest penetration assumptions into the MS and NS markets.
Questcor overhang removed, says Oppenheimer
After an investor blog published its second article which was critical of Questcor, Oppenheimer believes the article has little credibility. while the blog's objectiveness is questionable. The firm maintains an Outperform rating on the stock
Leerink remains positive on Questcor after second StreetSweeper report
As expected, QCOR soaring.
Hopefully some smarties picked up some earlier.
Second part posted on SS.
COMPLETE garbage article, fraud IMO.
QCOR: 2nd report from streetsweeper is out
StreetSweeper publishes second report on Questcor
TheStreetSweeper said via email that it just released the second story in its two-part investigative series on Questcor. The second report looks at Questcor's business strategy practices to resurrect Acthar, the online blog said
StreetSweeper covered 14,524 shares of Questcor short position yesterday
TheStreetSweeper disclosed on its website that it covered 14,524 shares of its short position in Questcor on January 25 at a price of $36.50 a share. The online blog now holds a 29,942 share short position in Questcor ahead of its second report on the company. :theflyonthewall
The article is garbage. It certainly didn't live up to the hype but it did do damage and allowed streetsweeper and other institutions to make money. As you know, streetsweeper was shorting the stock prior to releasing the rumor. They covered their position and then posted the article. This is blatantly illegal but the SEC will not do a thing about it.
The StreetSweeper Publishes Cautious Report on Questcor Pharmaceuticals
http://www.thestreetsweeper.org/
(report not very interesting, why stock jumped)
4.3 MILLION SHARE BUYBACK ALREADY AUTHORIZED.. please fry these clowns Mr. Bailey...
Buying calls into earnings.
Sorry I don't have PM to reply to your HALO PM.
No special insights into the company I've been a shareholder for a while. I think the VPHM deal may be underestimated in terms of potential. I also think HyQ could turn our to be very significant. A bit disappointed with how Roche partnership is shrinking but still have 2 great opportunities.
The stock seems to be attracting a bigger following these days. Though Cramer seems to have no idea about us (we don't really have meaningful product revenues) surprised it made a mention in his show.
FYI there is a HALO board if your interested.
So as not to be totally off topic. QCOR is a company I had looked at and passed on years ago what a great investment it would have been!
who do believe this stock is going down, well sell them to me... lol
QCOR Alert in News Feed
See the research on theflyonthewall.com
News Breaks
January 17, 2012
09:20 EDT QCOR theflyonthewall.com: Pre-market top 5 gainers
The following stocks were the top percentage gainers before the open on solid volume of at least 50,000 shares, trading at over $10. CNVO 48%, TSLA 14%, QCOR 5.2%, FCX 2.3%, RIG 2%. :theflyonthewall.com
07:29 EDT QCOR theflyonthewall.com: Questcor report from StreetSweeper may have little substance, says Jefferies
Jefferies believes StreetSweeper's questions to Questcor yesterday indicate the blog's preliminary allegations against the company may have very little substance. The firm wonders why StreetSweeper covered nearly half of its 80K short position before issuing its report telling investors why they should sell the stock. Jefferies keeps a Buy rating on Questcor shares with a $50 price target. :theflyonthewall.com
07:18 EDT QCOR theflyonthewall.com: Questcor answers to reporter do not point to illegal marketing, says Leerink
Leerink believes Questcor's answers to a StreetSweeper.org reporter were reasonable and do not point to illegal marketing conduct by the company. The firm believes shares of Questcor offer an excellent risk/reward profile at current levels and maintain an Outperform rating on the stock. :theflyonthewall.com
05:58 EDT QCOR theflyonthewall.com: Questcor believes thetreetsweeper.org is a fraud
On January 9 Questcor Pharmaceuticals received a communication from an individual representing herself to be associated with a website identified as StreetSweeper.org. The individual requested that the company provide responses to a series of questions about the company by January 10. Due to management's schedule, the individual was offered an opportunity to have the questions answered by management on Monday, January 16. Questcor has been unable to determine the exact nature of StreetSweeper.org, its ownership structure, or its revenue sources. The website, thestreetsweeper.org, provides no information on these topics, and standard listings about it are limited and opaque. Based on our exam ination to date, we believe that the website lists people that it claims are associated with it, one of whom the website and media reports identify as a felon who pled guilty to two conspiracy charges and who later pled guilty to racketeering charges related to stock manipulation, another of whom has the same name as an individual who, according to media reports, was arrested recently for kidnapping and extortion, and another of whom has the same name as an individual who, according to media reports, has been involved in extensive litigation regarding fraud, defamation, and slander. :theflyonthewall
Great time to buy.
StreetSweeper shorting at the same time CEO was selling stock (and at a time which everyone knew). Irony?
And all questions were answered fairly. If QCOR was hiding something they would not have responded at all.
Acthar ok'd by FDA since 1952 and given away for free for some children's hospitals. C'mon SS bastards, think of the children!
QCOR responds to the garbage from streetsweeper
http://finance.yahoo.com/news/Questcor-Pharmaceuticals-prnews-3875109327.html?x=0
10:51 Questcor CEO Says If there is Substantial Allegation, We Will Deal with It and Move On
QCOR bouncing.
10:04 Questcor CEO Calls Street Sweeper Article a 'Short Attack'
10:07 Questcor CEO Says Growth Driven by On-Label Sales and Strong Salesforce
10:14 Questcor CEO Says Next Growth Phase is From Use of Acthar in Lupus Patients
10:18 Questcor Pharma CEO Sees Acthar Market Oppotunity $2B+
10:33 (Dow Jones) Questcor (QCOR) didn't elaborate further on a negative report expected to be published by the blog Street Sweeper next week. At a healthcare conference Thursday, company reiterated a statement it previously issued in defending its marketing practices. "We really don't want to get distracted with this particular issue," said CEO Don Bailey . "We're here today to talk about QCOR and its value proposition for investors." QCOR shares down 2.2% to $34.56 .
hope you didn't get burned on this b/s today. what was done was downright illegal imo. Its one thing to be a whistle blower, its another thing when you hold a position that favors the action.That is called front running.
i was lucky and flipped out of my calls early on the 9th.. but sat and thought about adding yesterday again, and man am i grateful i didn't.
will have it on my radar again tomorrow tho, best of luck dude.
~QCOR~on watch
[img]stockcharts.com/c-sc/sc?s=QCOR&p=D&b=5&g=0&i=t53951210283&r=4203
[/img]
If I'm reading this correctly, I see big block trades at 35.79 (50K) and 35.39 (34K).
You don't have to buy their product if you feel that it is too expensive.
Naturally the "analysts" all come out and try to defend their high price targets. QCOR basically took a 40 year old drug and upped the price 15325346%. Everyone had a problem with that "pig" KV.A doing it, but QCOR is okay? If a Congressperson gets ahold of them they are finished and would look like AVNR and KV.A
Cowen and Jefferies are also defending QCOR.
Caris recommends buy on weakness and today raised price target to $55 from $46. Click Here
TheStreetSweeper.org, the Website noted for unearthing corporate fraud in public companies across scores of industries has initiated a short position in Questcor Pharmaceuticals (Nasdaq: QCOR) and news of that short trade has shares of the biotech company plunging more than 11% in early afternoon trading.
TheStreetSweeper will issue a two-part investigative article on California -base Questcor with the first part scheduled to be released early next week.
The first article raises serious questions about the aggressive marketing practices that QCOR has used to generate explosive – but potentially unsustainable – growth in prescriptions for its only drug while the second story further examines QCOR's business practices, while taking a hard look at the leaders who have struck it rich as a result of the company's controversial growth strategy, according to an e-mail issued by TheStreetSweeper.
TheStreetSweeper said it "has sold 80,599 shares of QCOR short at an average price of $41.46 a share in anticipation of a future decline in the stock price."
Questcor's primary product is H.P. Acthar Gel (repository corticotropin injection), an injectable drug for the treatment of acute exacerbations of multiple sclerosis; infantile spasms in infants and children under two years of age; nephrotic syndrome; and Lupus.
Shares of Questcor had risen more than 150% in the past year prior to today, but selling pressure in the stock is intense as volume has reached more than seven times the daily average, forcing the stock below support at $40.
(retrieved from TDA news stream)
Well, we nearly filled the gap and they are projected to earn somewhere around $1.90 in 2012 if memory serves. I bit and took a partial position. I have trend support around the 200DMA and will follow this story. In my opinion, their 'Marketing Strategy' is working.
Ironic SS starts this up prior to QCOR conference presentation.
Sounds like someone is shorting.
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
407
|
Created
|
04/30/09
|
Type
|
Free
|
Moderators |
At Questcor, we are a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Our efforts are currently focused on the fields of neurology and nephrology, areas of medicine which have significant unmet medical needs.
Our highly experienced Sales and Marketing teams are presently focused on increasing the usage of our primary marketed product, Acthar, among specialists who treat patients with multiple sclerosis, infantile spasms and nephrotic syndrome. In addition, our Medical Affairs personnel are working with leading researchers to explore promising additional uses for this important product in a variety of other conditions.
How we implement our business strategy:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |